Correlation between Fas and FasL proteins expression in normal gastric mucosa and gastric cancer

Folia Histochemica et Cytobiologica

Volumn 49, Issue 1, 2011, Pages 142-147

  Gryko, Mariusz ^a   Guzińska Ustymowicz, Katarzyna ^a   Pryczynicz, Anna ^a   Cepowicz, Dariusz ^a   Kukliński, Adam ^a   Czyzewska, Jolanta ^a   Kemona, Andrzej ^a   Kedra, Bogusław ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Fas; FasL; Gastric cancer; Helicobacter pylori

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CONTROLLED STUDY; FEMALE; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH EPITHELIUM; STOMACH MUCOSA;

HELICOBACTER PYLORI;

EID: 79958114194     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0020     Document Type: Article

References (16)

1. Bjelakovic G, Nagorni A, Bjelakovic M, Stamenkovic I, Ar-sic R, Katić V. Apoptosis: programmed cell death and its clinical implications. Medicine and Biology. 2005;12:6-11.
2. Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol. 2004;4:321-326.
3. Lee H, Ferguson TA. Biology of Fas L. Cytokine Growth Factor Rev. 2003;14:325-335.
4. Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat. 2006;9:51-73.
5. Ishihara S, Fukuda R, Kawashima K et al. T cell-mediated cytotoxicity via Fas/Fas ligand signaling in Helicobacter pylori-infected gastric corpus. Helicobacter. 2001;6:283-293.
6. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol. 2001;127:20-26.
7. Liu H, Ubukata H, Nakaschi T et al. The distribution and intracellular location of Fas and Fas ligand following gastric carcinogenesis: Fas ligand expressing gastric carcinoma cells can inhibit local immune response. Mol Cell Biochem. 2009;331 181-186.
8. Ohno S, Tachibana M, Shibakita M et al. Prognostic significance of Fas and Fas ligand system associated apoptosis in gastric cancer. Ann Surg Oncol. 2000;7:750-757.
9. Yoshikawa T, Saito H, Osaki T, Matsumoto S, Tsujitani S, Ikeguchi M. Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer. J Surg Res. 2008;148:143-148.
10. Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroen-terol 2003;7:1415-1420.
11. Osaki M, Kase S, Kodani I, Watanabe M, Adach H, Ito H. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinoma: correlation with proliferation and apoptosis. Gastri Cancer. 2001;4:198-205.
12. Lim SC. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncol Rep. 2002;9:103-107.
13. Benett M W, O'Connell J, O'Sullivan GC et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999;44:156-162.
14. Houghton JM, Korah R, Harrisom LE, Clarke KO, Michel JJ. Fas ligand expression on intestinal type gastric carcinoma but not diffuse type: evidence for immune evasion. Am J Gastroenterol. 2001;9:57.
15. Wang J, Chi DS, Kalin GB et al. Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci. 2002;47:7-13.
16. Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric car-cinogenesis. Am J Gastroenterol. 2001;96:16-26.